# ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

> **NCT00140595** · PHASE3 · COMPLETED · sponsor: **Lymphoma Study Association** · enrollment: 380 (estimated)

## Conditions studied

- Diffuse Large-Cell Lymphoma

## Interventions

- **DRUG:** rituximab
- **DRUG:** doxorubicin
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT00140595
- **Lead sponsor:** Lymphoma Study Association
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2011-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140595, "ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00140595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*